NPC(SH:600713) Shang Hai Zheng Quan Bao·2025-08-29 20:06Core Viewpoint - The company has released its 2025 semi-annual report, which includes details on financial performance, profit distribution, and the management of raised funds [3][9][30]. Group 1: Company Overview - The company is named Nanjing Pharmaceutical Co., Ltd., with stock code 600713 and bond code 110098 [5]. - The board of directors and supervisory board confirm the authenticity and completeness of the report [1][28]. Group 2: Financial Data - The company did not distribute profits during the reporting period, but plans to distribute a cash dividend of 1.70 yuan per 10 shares, totaling approximately 222.47 million yuan [3]. - The total amount raised from the issuance of convertible bonds was approximately 1.08 billion yuan, with a net amount of about 1.07 billion yuan after deducting issuance costs [13]. Group 3: Fund Management - As of June 30, 2025, the balance of the raised funds was approximately 124.10 million yuan [14]. - The company has established special accounts for the management of raised funds, ensuring compliance with relevant regulations [15]. - The company has not used idle raised funds to temporarily supplement working capital [18]. Group 4: Board and Supervisory Meetings - The board of directors held its third meeting on August 28, 2025, where all proposals were approved unanimously [8][9]. - The supervisory board also approved the semi-annual report and the special report on the management of raised funds, with no dissenting votes [30][31].